低反应患者促排卵期间的辅助用药
本文为简短叙述性综述,总结生长激素、来曲唑和枸橼酸氯米芬在卵巢低反应患者体外受精(IVF)周期中的证据。作者认为生长激素可减少取卵所需促排卵、增加获卵数并改善临床妊娠率,但活产证据不足;来曲唑和枸橼酸氯米芬可减少促性腺激素用量,但不改善活产率。
要点
- 生长激素可能减少取卵所需促排卵、增加获卵数并改善临床妊娠率。
- 生长激素提高活产率的证据目前不足。
- 来曲唑和枸橼酸氯米芬可减少促性腺激素用量,但不改善活产率。
核心结论
- 作者认为卵巢低反应女性使用生长激素可减少取卵所需促排卵、增加获卵数并改善临床妊娠率,但目前证据不足以明确其提高活产率。
- 在相同情况下,来曲唑和枸橼酸氯米芬可减少取卵前促性腺激素需求,但不改善活产率。
研究设计与样本
- 简短叙述性综述,总结生长激素、来曲唑和枸橼酸氯米芬用于卵巢低反应患者IVF周期的证据。
- 原文指出生长激素、来曲唑和枸橼酸氯米芬未获美国食品药品监督管理局(FDA)批准用于IVF周期。
主要发现
- 生长激素可减少取卵所需促排卵、增加获卵数并改善临床妊娠率。
- 目前证据不足以明确生长激素提高活产率。
- 来曲唑和枸橼酸氯米芬可减少取卵前促性腺激素需求,但活产率无改善。
关键数值与推荐
- 生长激素、来曲唑和枸橼酸氯米芬未获美国食品药品监督管理局(FDA)批准用于IVF周期。
临床怎么用
- 原文指出这些辅助用药的证据基础可能有限,其使用可能基于经验而非证据。
- 原文未据此给出推荐。
局限性
- 涉及卵巢低反应女性辅助用药的研究常因招募已接受多个失败IVF周期女性困难及活产率必然偏低而把握度不足。
- 招募脆弱女性进入含安慰剂组的研究存在困难,进一步加剧上述问题。
- 这些辅助用药的证据基础可能有限,其使用可能基于经验而非证据。
- 目前证据不足以明确生长激素提高活产率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Growth hormone, letrozole, and clomiphene citrate do not have US Food and Drug Administration approval for their use in in vitro fertilization (IVF) cycles. However, despite this fact, they often are used to augment the IVF cycle in women considered "low responders." Unfortunately, because of the problems inherent to recruiting women who have undergone several unsuccessful IVF treatment cycles, and their inevitable low live birth rate, studies involving adjuvants for women considered low responders to ovarian stimulation often are underpowered. This is compounded further by the difficulty in recruiting vulnerable women to a study with a placebo arm. Consequently, the evidence base for their use as adjuncts to IVF treatment may be limited, and consequently their use may be empirical rather than evidence based. This short narrative review describes the evidence for these "add-ons" for a patient with a low response to ovarian stimulation. It suggests that a woman with a low ovarian response will derive benefit from using growth hormone; with a reduction in the ovarian stimulation required for oocyte retrieval, collection of a greater number of oocytes, and improvement in the clinical pregnancy rate. Although there currently is insufficient evidence to state categorically that it leads to an increased chance of a live birth. In the same situation, clomiphene citrate and letrozole lead to a reduced requirement for gonadotropins before oocyte retrieval, but with no improvement in live birth rate for their use.
引用
- Hart RJ. Stimulation for low responder patients: adjuvants during stimulation. Fertil Steril. 2022. PMID: 35256192. doi:10.1016/j.fertnstert.2022.01.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。